The University of Chicago Header Logo

Connection

Jay Koyner to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Jay Koyner has written about Antibodies, Monoclonal, Humanized.
Jay Koyner
Connection Strength
0.150
Antibodies, Monoclonal, Humanized
  1. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
    View in: PubMed
    Score: 0.150
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.